Response

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (PL, JAM, CSF, SO); Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK (PL); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (CSF); Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (SO); Department of Epidemiology, Harvard School of Public Health, Boston, MA (SO).
² Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (PL, JAM, CSF, SO); Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK (PL); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (CSF); Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (SO); Department of Epidemiology, Harvard School of Public Health, Boston, MA (SO). shuji_ogino@dfci.harvard.edu.

Comment

Paul Lochhead et al. J Natl Cancer Inst. 2014.

. 2014 Aug 11;106(8):dju181.

doi: 10.1093/jnci/dju181. Print 2014 Aug.

¹ Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (PL, JAM, CSF, SO); Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK (PL); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (CSF); Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (SO); Department of Epidemiology, Harvard School of Public Health, Boston, MA (SO).
² Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (PL, JAM, CSF, SO); Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK (PL); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (CSF); Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (SO); Department of Epidemiology, Harvard School of Public Health, Boston, MA (SO). shuji_ogino@dfci.harvard.edu.

No abstract available

Comment on

Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.
Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, Qian ZR, Morikawa T, Shen J, Meyerhardt JA, Fuchs CS, Ogino S. Lochhead P, et al. J Natl Cancer Inst. 2013 Aug 7;105(15):1151-6. doi: 10.1093/jnci/djt173. Epub 2013 Jul 22. J Natl Cancer Inst. 2013. PMID: 23878352 Free PMC article.
Re: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.
Rosty C, Williamson EJ, Clendenning M, Walters RJ, Walsh MD, Win AK, Jenkins MA, Hopper JL, Winship I, Southey MC, Giles GG, English DR, Buchanan DD. Rosty C, et al. J Natl Cancer Inst. 2014 Aug 11;106(8):dju180. doi: 10.1093/jnci/dju180. Print 2014 Aug. J Natl Cancer Inst. 2014. PMID: 25114271 No abstract available.